1. Home
  2. STAA vs BEAM Comparison

STAA vs BEAM Comparison

Compare STAA & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo STAAR Surgical Company

STAA

STAAR Surgical Company

N/A

Current Price

$25.99

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

N/A

Current Price

$25.80

Market Cap

2.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
STAA
BEAM
Founded
1982
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Ophthalmic Goods
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
2.3B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
STAA
BEAM
Price
$25.99
$25.80
Analyst Decision
Hold
Strong Buy
Analyst Count
10
12
Target Price
$24.56
$48.09
AVG Volume (30 Days)
1.3M
1.9M
Earning Date
11-05-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$230,591,000.00
$55,701,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$22.61
$26.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.50
$13.53
52 Week High
$30.81
$35.25

Technical Indicators

Market Signals
Indicator
STAA
BEAM
Relative Strength Index (RSI) 52.87 50.81
Support Level $23.03 $25.86
Resistance Level $25.35 $28.10
Average True Range (ATR) 1.18 1.66
MACD -0.02 0.03
Stochastic Oscillator 69.56 39.97

Price Performance

Historical Comparison
STAA
BEAM

About STAA STAAR Surgical Company

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: